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Ependymomas are common childhood brain tumors, but little is known about their underlying biology. In this
issue of Cancer Cell, Witt et al. present that posterior fossa ependymomas comprise two distinct molecular
subtypes, each with unique gene expression signatures, different levels of genomic instability, and different
prognosis.Althoughmore common in children, epen-
dymomas occur in both children and
adults. They arise in supratentorial, poste-
rior fossa, or spinal levels of the neuraxis
from ependymal cells that line the walls
of the ventricles. As remnants of the prolif-
erative ventricular zone, ependymal cells
are hypothesized to be an adult multi-
potent stem cell (Pevny and Rao, 2003).
This is corroborated by evidence that
ependymomas express both neuronal
and glial markers (Pevny and Rao, 2003).
It is hypothesized that since ependymal
cells aremaintained as proliferating neural
progenitors beyond the postnatal period,
this leaves them susceptible to oncogenic
transformation.
Clinically, ependymomas remain an
enigma to neuro-oncologists and neuro-
surgeons. As chemotherapy has yet to
demonstrate any improvement in overall
survival from this disease, maximal sur-
gical removal followed in some cases by
external beam radiation is the current
standard of care. The clinical outcome is
quite variable for patients diagnosed with
ependymoma, but approximately 50% of
patients do not survive more than five
years (Dubuc et al., 2010).
One major barrier to improving patient
outcome has been our inability to predict
the clinical behavior of the tumors and
thus determine which patients would
benefit from adjuvant therapy. Histolog-
ical grading as per theWorld Health Orga-
nization criteria has been insufficient in
accurately predicting patient outcome,
and complete resection of the tumor has
only variably been associated with im-
proved patient survival; moreover, meta-
static seeding into cerebrospinal fluid
spaces remains problematic. Efforts to
identify prognostic molecular markersgenerated early enthusiasm, but the
degree to which they could accurately
predict outcome was limited. Specifically,
epidermal growth factor receptor family
proteins (ERBB1, 2, and 4) appear to be
promising markers of poor prognosis
and potential indicators for response to
targeted therapy, yet clinical trials of
inhibitors of the ERBB pathway have
not been effective in improving survival
(Gilbertson et al., 2002; Jakacki et al.,
2008; Zacharoulis and Moreno, 2009).
To date, the most consistent molecular
marker for poor prognosis is a gain of
chromosome 1 (Carter et al., 2002), but
the salient genes affected by this chromo-
somal copy number alteration have not
been identified.
A series of recent breakthrough studies
have begun to uncover the biology of
ependymomas. Using genomic technolo-
gies to identify molecular and biological
subtypes previously hidden within the
tumor class, insights into the tumor’s cell
of origin have been made particularly for
supratentorial ependymomas. Supraten-
torial ependymomas comprise one third
of all ependymomas and are three times
more common in children than adults.
Using gene expression profiles, Taylor
et al. (2005) proposed radial glia as the
cell of origin for supratentorial and spinal
cord ependymomas. They were able to
purify cancer stem cells based on the
CD133+/RC2+/BLPB+ immunophenotype
and showed upregulation of EphB-Ephrin
and Notch signaling pathways in these
supratentorial tumors. Building on the
importance of Ephrin signaling, Johnson
et al. (2010) generated the first mouse
model for supratentorial ependymomas.
Mice transplanted with mouse neural
stem cells with loss of Ink4a/Arf activityCancer Cell 20and overexpression of Eph2b developed
brain tumors.
Work from Taylor, Pfister, and col-
leagues presented in this issue specifi-
cally focus on posterior fossa ependy-
moma (Witt et al., 2011). They profiled
the transcriptome of 177 primary poste-
rior fossa ependymomas from two sepa-
rate cohorts and used unsupervised clus-
tering methods for class discovery. Their
analysis identified two distinct subtypes
of posterior fossa ependymoma, termed
subtypes A and B, which highly correlated
with age, location of tumor, biological
signaling pathways, genomic instability,
and prognosis (Figure 1). The subtypes
identified by these methods were highly
concordant with and reproducible in an
independent patient cohort.
Subtype A tumors occurred in younger
patients, were more likely to be found
extending laterally into the cerebellopon-
tine angle, and had a gender bias as
70% male (Figures 1A and 1B). Tumors
in this subtype had relatively less genomic
instability; the most frequent DNA copy
number variants included gain of chromo-
some1or lossof chromosome22. Tumors
of subtype B, on the other hand, occurred
in older patients and were more likely to
be found in the spinal cord or the midline
of the cerebellum. This subtype had a
muchhigherdegreeof genomic instability,
with extensive chromosomal aberrations
(Figure 1C). An analysis of clinical out-
comes for each disease found subtype A
tumors to have worse prognosis, with
56% of patients eventually having recur-
rent disease and 35% of patients dying
of their disease within five years (Figure
1C). Patients with Subtype B tumors had
a 25% and 5% rate of recurrence and
death within five years, respectively., August 16, 2011 ª2011 Elsevier Inc. 133
Figure 1. Two Distinct Subtypes of Posterior Fossa Ependymoma
(A) Schematic of human CNS indicates location of tumor in either group. Group A is more likely to form
tumors in the ventricle, which can grow through the Foramina of Luschka into the extra-axial space
surrounding the brain stem and cerebellum (pink). Group B tumors form either within the ventricle (pink)
or in the central canal of the spinal cord (blue), causing distention.
(B) Patient median age and gender bias of each subtype.
(C) Pie chart indicates the percent of patients that survive without cancer progression for at least five years.
The lists of overexpressed signaling pathways in each group and common chromosome abnormalities are
superimposed on the pie charts.
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identified signaling pathways enriched
in each disease subtype (Figure 1C).
Subtype A had enrichment of genes asso-
ciated with signaling pathways for angio-
genesis, PDGF, MAPK, EGFR, TGF-b,
integrins, extracellular matrix (ECM) as-
sembly, RAS/GTPase, and tyrosine kinase
receptor signaling. Subtype B tumors
were found to overexpress genes as-
sociated with ciliogenesis, microtubule
assembly, and mitochondria/oxidation
metabolism. These findings were vali-
dated using immunohistochemical anal-134 Cancer Cell 20, August 16, 2011 ª2011 Eysis. As Subtype A had overexpression
of ECM assembly, two markers of ECM
signaling, Tenascin-C and Laminin alpha-
2, were selected, while ciliogenesis sig-
naling and microtubule assembly markers
indicative of Subtype B were assayed,
specifically Kinesin Family Member-27,
and Neural Epidermal Growth Factor
Like-2. The authors show that commer-
cially available antibodies against these
proteins were robust and suggested
their potential use in clinical pathology
labs to help risk-stratify ependymoma
patients.lsevier Inc.In summary, what emerges from this
study is the clear delineation of two sub-
types of posterior fossa ependymoma—
one with a predilection for younger chil-
dren and associated with high mortality
and morbidity and the other arising in
both children and adults with better prog-
nosis—that can be efficiently identified
using standard and widely available
immunohistochemical techniques. Look-
ing forward, once further validated in pro-
spective clinical studies, the molecular
markers presented here could be used
to identify the ependymoma patients
most ‘‘at risk’’ for recurrence and in need
of maximal adjuvant therapy. This study
also provides a foundation from which
driver genes and signaling pathways
controlling the growth of various epen-
dymoma subtypes can be identified,
ushering in newer, targeted, and more
effective treatment strategies.REFERENCES
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